

Supplementary Tables

Table S1. Univariate logistic regression (Response: VTE)

Table S2. BVAS Univariate Analysis, Cyclophosphamide/Rituximab Use

Table S3. VDI Univariate Analysis

Table S1. Univariate logistic regression (Response: VTE)		
Characteristic	OR (95% CI)	p-value
Age of onset (y)	0.99 (0.97, 1.02)	0.82
Female sex	1.17 (0.5, 3.1)	0.75
Length of Follow-up (months)	0.99 (0.99, 1.00)	0.28
BMI (kg/m ²)	1.1 (1.1, 1.2)	0.001*
PR3 ANCA	4.4 (1.6, 16.0)	0.01*
Obesity (BMI ≥ 30 kg/m ²)	3.6 (1.4, 10.1)	0.009*
Weight (kg)	1.03 (1.01, 1.05)	0.004*
C-reactive Protein (mg/L)	1.01 (0.98, 1.03)	0.51
RPGN	3.47 (1.38, 8.89)	0.008*
Alveolar Hemorrhage	3.42 (0.98, 10.71)	0.04
Hypoalbuminemia (<3.0 g/dL)	5.70 (2.22, 15.03)	<0.001*
Rituximab Induction	2.33 (0.87, 7.43)	0.11
Cyclophosphamide induction	0.64 (0.24, 1.59)	0.35
History of Malignancy	∅	0.99
BVAS Level at time of diagnosis (Low, Medium, High, Extreme)	1.82 (1.06, 3.30)	0.04*

Abbreviations used: BMI (body mass index), PR3 (proteinase-3 ANCA), RPGN (Rapidly Progressive Glomerulonephritis), BVAS (Birmingham Vasculitis Activity Score)

Table S2. BVAS Univariate Analysis, Cyclophosphamide/Rituximab Use		
Characteristic	OR (95% CI)	p-value
BVAS General	0.88 (0.35, 2.16)	0.79
BVAS Cutaneous	3.32 (1.19, 8.92)	0.02*
BVAS Mucous Membranes	0.99 (0.23, 3.05)	0.99
BVAS ENT	1.36 (0.54, 3.48)	0.51
BVAS Chest	4.01 (1.41, 14.43)	0.02*
BVAS Cardiovascular	∅	0.99
BVAS Abdominal	∅	0.99
BVAS Renal	2.34 (0.74, 10.38)	0.19
BVAS Nervous System	∅	0.99
Cyclophosphamide Use	0.55 (0.20, 1.41)	0.23
Rituximab Use	2.95 (1.03, 10.68)	0.06

Table S3. VDI Univariate Analysis		
Characteristic	OR (95% CI)	p-value
VDI at 12 months	1.60 (0.85, 3.13)	0.15
VDI at 60 months	1.51 (0.66, 3.49)	0.31
VDI at end of follow-up	1.37 (0.81, 2.35)	0.23